Skip to main content

Table 1 Characteristics of study sample by treatment group

From: Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?

  Platinum Taxane Platinum plus Taxane Other P
Contrast-enhanced CTs, n 1249 385 182 2129  
Median duration of treatment, d [range] 70 [1–502] 77 [1–483] 50 [1–258] 73 [1–707] < 0.0001
Mean no. of CTs per patient (SD) 1.72 (1.07) 2.18 (1.59) 1.55 (0.78) 2.42 (1.82) < 0.0001
Median patient age at CT, y [range] 65 [18–87] 64 [23–86] 61 [23–80] 66 [21–91] < 0.0001
Primary tumor      
   Gastrointestinal 618 (49.5%) 12 (3.1%) 27 (14.8%) 541 (25.4%) < 0.0001
   Urogynecological 160 (12.8%) 129 (33.5%) 115 (63.2%) 266 (12.5%)  
   Breast 47 (3.8%) 176 (45.7%) 8 (4.4%) 523 (24.6%)  
   Lung 305 (24.4%) 50 (13%) 10 (5.5%) 271 (12.7%)  
   Hematological 6 (0.5%) 1 (0.3%) 2 (1.1%) 207 (9.7%)  
   Melanoma 44 (3.5%) - 5 (2.8%) 128 (6%)  
   Other sites 69 (5.5%) 17 (4.4%) 15 (8.2%) 193 (9.1%)  
ICM-related ARs, n (%) 9 (0.7) 5 (1.3) 4 (2.2) 22 (1.0)* 0.221
  1. Abbreviations: Other, any chemotherapy without platinum or taxane; n number, d days, y years, CT computed tomography, SD standard deviation, ICM iodinated contrast media, AR adverse reaction.
  2. *4 ARs with vinca alkaloid-based therapy; 3 with anthracycline-based therapy; 3 with fluorouracil-based therapy; 3 with tyrosine kinase inhibitors; 2 with IL2; 2 with gemcitabine; 1 with irinotecan; 1 with fotemustine; 1 with bevacizumab; 1 with interferon; 1 with ipilimumab.